Summary
The provided label excerpts only support stewardship/indication-use-responsibly language about treating or preventing proven/strongly suspected susceptible bacterial infections and resistance risk. The AI-generated statements largely concern pricing, availability, insurance coverage, patent status, and multiple specific clinical uses/side effects, none of which are supported by the supplied prescribing information excerpts. Several clinical use statements are unsupported because they are not present in the provided label text.
Category Scores
Accurate Statements
Doxycycline hyclate is a broad-spectrum tetracycline antibiotic.
Not supported by the supplied label excerpts (only stewardship/indication-use-responsibly and resistance risk text was provided).
Doxycycline hyclate is used to treat a variety of bacterial infections.
Only general stewardship language is present in the supplied excerpts; specific “used to treat…” claims are not stated in the provided label text.
To reduce the development of drug-resistant bacteria, doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria; when available, culture and susceptibility information should be considered.
Supported by Section 1 INDICATIONS AND USAGE excerpt: use only for proven or strongly suspected susceptible bacteria; consider culture/susceptibility information when available.
Prescribing doxycycline hyclate delayed-release tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit and increases the risk of the development of drug-resistant bacteria.
Supported by Section 5.10 Development of Drug-Resistant Bacteria excerpt.
Unsupported Statements
Doxycycline hyclate price varies depending on dosage, quantity, and the specific pharmacy or retailer.
Pricing information is not contained in the supplied prescribing information excerpts.
Generic doxycycline hyclate is widely available.
Availability/manufacturing market statements are not contained in the supplied prescribing information excerpts.
Generic doxycycline hyclate is generally an affordable medication.
Affordability/pricing claims are not contained in the supplied prescribing information excerpts.
For 30 tablets of 100 mg generic doxycycline hyclate, prices can range from approximately $4 to $20.
Pricing ranges are not contained in the supplied prescribing information excerpts.
Prices for 30 tablets of 100 mg generic doxycycline hyclate can be lower with discount cards.
Discount card/pricing program claims are not contained in the supplied prescribing information excerpts.
Prices for 30 tablets of 100 mg generic doxycycline hyclate can be lower when purchasing larger quantities.
Bulk purchase pricing claims are not contained in the supplied prescribing information excerpts.
A 90-day supply of generic doxycycline hyclate might cost between $10 and $40.
Pricing range claims are not contained in the supplied prescribing information excerpts.
Prices can differ significantly between pharmacies.
Pricing comparisons are not contained in the supplied prescribing information excerpts.
Online pharmacies and discount programs often offer lower prices than traditional brick-and-mortar drugstores.
Store-type/online pricing comparisons are not contained in the supplied prescribing information excerpts.
Doxycycline hyclate is available in various forms, including capsules and tablets.
Dosage form/manufacturer formulation availability beyond the provided label excerpts is not contained in the supplied prescribing information excerpts.
Common strengths of doxycycline hyclate include 100 mg and 50 mg.
Specific strength availability is not contained in the supplied label excerpts.
The form and strength may influence the cost of doxycycline hyclate.
Cost drivers are not contained in the supplied label excerpts.
Generic versions of all standard formulations of doxycycline hyclate are generally inexpensive.
Economic/market statements are not contained in the supplied label excerpts.
Doxycycline hyclate is typically covered by most prescription drug insurance plans.
Insurance coverage statements are not contained in the supplied label excerpts.
The exact cost of doxycycline hyclate to the patient with insurance depends on the specific plan's formulary, deductible, and co-payment or co-insurance.
Insurance/cost-sharing details are not contained in the supplied label excerpts.
The original patents for doxycycline hyclate have long since expired.
Patent/legal history is not contained in the supplied label excerpts.
Lack of patent protection allows for widespread production and sale of generic doxycycline hyclate by multiple manufacturers.
Patent/legal history and generic market production statements are not contained in the supplied label excerpts.
Numerous pharmaceutical companies produce generic doxycycline hyclate.
Manufacturer/market production statements are not contained in the supplied label excerpts.
Multiple manufacturers offer generic doxycycline hyclate in various formulations.
Manufacturer/formulation availability statements are not contained in the supplied label excerpts.
Doxycycline hyclate is a broad-spectrum tetracycline antibiotic.
Class/breadth description is not contained in the supplied label excerpts.
Doxycycline hyclate is used to treat a variety of bacterial infections.
Specific indication-use statements are not contained in the supplied label excerpts (only stewardship guidance about suspected/proven susceptible bacterial infections is included).
Doxycycline hyclate is used to treat respiratory tract infections.
Specific indication (respiratory tract infections) is not contained in the supplied label excerpts.
Doxycycline hyclate is used to treat urinary tract infections.
Specific indication (urinary tract infections) is not contained in the supplied label excerpts.
Doxycycline hyclate is used to treat skin infections.
Specific indication (skin infections) is not contained in the supplied label excerpts.
Doxycycline hyclate is used to treat certain sexually transmitted infections.
Specific indication (STIs) is not contained in the supplied label excerpts.
Doxycycline hyclate is used for malaria prevention and treatment.
Specific indication (malaria prevention/treatment) is not contained in the supplied label excerpts.
Doxycycline hyclate is used for acne.
Specific indication (acne) is not contained in the supplied label excerpts.
Common side effects associated with doxycycline hyclate can include nausea.
Adverse reaction/side effect examples are not contained in the supplied label excerpts.
Common side effects associated with doxycycline hyclate can include vomiting.
Adverse reaction/side effect examples are not contained in the supplied label excerpts.
Common side effects associated with doxycycline hyclate can include diarrhea.
Adverse reaction/side effect examples are not contained in the supplied label excerpts.
Common side effects associated with doxycycline hyclate can include photosensitivity (increased sensitivity to sunlight).
Adverse reaction/side effect examples are not contained in the supplied label excerpts.
Less common but more serious side effects can also occur with doxycycline hyclate.
Adverse reaction frequency/seriousness statements are not contained in the supplied label excerpts.
Contradictions
Important Omissions
The AI-provided content does not supply FDA-label details for dosage and administration, contraindications, boxed warnings, full warnings/precautions beyond drug-resistance stewardship, drug interactions, specific populations, monitoring, or storage/handling.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only on-label safety-relevant content visible in the supplied label excerpts concerns appropriate use to reduce resistance. However, the response also includes multiple unsupported clinical-use and adverse-effect statements, which could mislead if taken as label-supported guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Misaligned
Primary Issue
Most claims are not supported by the supplied FDA prescribing information excerpts (pricing/availability/insurance/patent/and specific indication and side-effect statements are not present).
Suggested Improvement
Limit claims to the provided label-supported stewardship guidance: use only for infections proven or strongly suspected due to susceptible bacteria; consider culture/susceptibility when available; prescribing without proven/strongly suspected infection or prophylactic indication is unlikely to provide benefit and increases risk of drug resistance. Remove or clearly label other statements as not derived from the FDA prescribing information provided.